The treatment of type 2 diabetes;Therapie des diabetes mellitus typ 2

Deutsches Arzteblatt International

Volumn 111, Issue 5, 2014, Pages 69-82

  Pfeiffer, Andreas F H ^a,b   Klein, Harald H ^c  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

CALORIC INTAKE; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SEDENTARY LIFESTYLE; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; LOW CARBOHYDRATE DIET; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME;

CALORIC RESTRICTION; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, CARBOHYDRATE-RESTRICTED; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84896825011     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0069     Document Type: Review

References (40)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.
2. DeFronzo RA: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270-87.
3. Paulweber B, Valensi P, Lindstrom J, et al.: A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010; 42(Suppl 1): 3-36.
4. Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives. Endocr J 2011; 58: 723-39.
5. th edition: www.idf.org/atlasmap/atlasmap (Last accessed on 13 Januaray 2014)
6. Seshasai SR, Kaptoge S, Thompson A, et al.: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-41.
7. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993; 77: 1287-93. (Pubitemid 23345484)
8. Markovic TP, Jenkins AB, Campbell LV, Furler SM, Kraegen EW, Chisholm DJ: The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998; 21: 687-94. (Pubitemid 28487056)
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
10. Wing RR, Lang W, Wadden TA, et al.: Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care 2011; 34: 1481-6.
11. Wing RR: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-75.
12. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R: Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506-14.
13. Selvin E, Steffes MW, Zhu H, et al.: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-11.
14. Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care 2010; 33(Suppl 1): 3.
15. Kerner W, Brückel J: Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie 2011; Suppl 2: 107-10.
16. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28(2): 103-17.
17. UK Prospective Diabetes Study (UKPDS): X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36: 1021-9.
18. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72. (Pubitemid 351831357)
19. Giani G, Janka HU, Hauner H, et al.: Epidemiologie und Verlauf des Diabetes mellitus in Deutschland. Evidenzbasierte Leitlinie DDG - Aktualisierung 05/2004. www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/ Evidenzbasierte-Leitlinien/EBL-Epidemiologie-Update-2004.pdf (last accessed on 9 October 2013).
20. Gerstein HC, Miller ME, Genuth S, et al.: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-28.
21. Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
22. Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
23. Hemmingsen B, Lund SS, Gluud C, et al.: Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898.
24. IQWiG. Nutzenbewertung einer langfristigen normnahen Blutzuckersenkung bei Patienten mit Diabetes mellitus Typ 2. IQWiG-Berichte - Jahr: 2011 Nr. 87 2011; www.iqwig.de/download/A05-07-Rapid-Report-Normnahe-Blutzuckersenkung-bei- Diabetes-mellitus-Typ-2.pdf (last accessed on 16 September 2012).
25. Zannad F, Stough WG, Pocock SJ, et al.: Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J 2012; 33: 1049-57.
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
27. st edition, Version 2. 2013 last updated on September 2013 Available from: www.versorgungsleitlinien.de/themen/ diabetes2/dm2-Therapie (last accessed on 11. January 2014).
28. Matthaei S, Bierwirth R, Fritsche A, et al.: Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Exp Clin Endocrinol Diabetes 2009; 117: 522-57.
29. Sacks DB, Arnold M, Bakris GL, et al.: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34: e61-e99.
30. American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care 2011; 34(Suppl 1): 11-61.
31. Gross JL, Kramer CK, Leitao CB, et al.: Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011; 154: 672-9.
32. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
33. Monami M, Colombi C, Balzi D, et al.: Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34: 129-31.
34. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800 000 individuals. BMC Cancer 2011; 11: 20.
35. Shaw JS, Wilmot RL, Kilpatrick ES: Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24: 1160-3. (Pubitemid 47437878)
36. Herrington WG, Levy JB: Metformin: effective and safe in renal disease? Int Urol Nephrol 2008; 40: 411-7.
37. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010: CD002967.
38. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010: CD002967.
39. Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467-73. (Pubitemid 34030749)
40. Murata GH, Duckworth WC, Hoffman RM, Wendel CS, Mohler MJ, Shah JH: Hypoglycemia in type 2 diabetes: a critical review. Biomed Pharmacother 2004; 58: 551-9. (Pubitemid 40260376)